Claims
- 1. A method of inhibiting H-2 histamine receptors which comprises administering to an animal in need of inhibition of said receptors in an effective amount to inhibit said receptors a heterocyclic compound of the formula: ##STR15## wherein A is such that there is formed together with the carbon atom shown an unsaturated heterocyclic nucleus, said unsaturated heterocyclic nucleus being an imidazole, pyrazole, pyrimidine, pyrazine or pyridazine ring; X.sub.1 is hydrogen, lower alkyl, hydroxyl, trifluoromethyl, benzyl, halogen, amino or ##STR16## in which E' is NH or N-cyano; X.sub.2 is hydrogen or when X.sub.1 is lower alkyl, lower alkyl or halogen; k is 0 to 2 and m is 2 or 3, provided that the sum of k and m is 3 or 4; Y is oxygen, sulphur or NH; E is NR.sub.2 ; R.sub.1 is hydrogen, lower alkyl or di-lower alkylamino-lower alkyl; and R.sub.2 is hydrogen, nitro or cyano, or a pharmaceutically acceptable addition salt thereof with the proviso that X.sub.1 is ##STR17## only when E is NH or N-cyano.
- 2. A method of claim 1 in which the heterocyclic compound is N-cyano-N'-methyl-N"-[2-((4-methyl-5-imidazolyl)-methylthio)ethyl]guanidine or a pharmaceutically acceptable addition salt thereof.
- 3. A method of claim 2 in which the heterocyclic compound is N-cyano-N'-methyl-N"-[2-((4-methyl-5-imidazolyl)-methylthio)ethyl]guanidine in the form of its free base.
- 4. A method of claim 3 in which the heterocyclic compound is administered orally.
- 5. A method of claim 3 in which the heterocyclic compound is administered in a daily dosage regimen of from about 150 mg. to about 1000 mg.
- 6. A method of inhibiting gastric acid secretion which comprises administering to an animal in need of inhibition of gastric acid secretion in an effective amount to inhibit gastric acid secretion a heterocyclic compound of the formula: ##STR18## wherein A is such that there is formed together with the carbon atom shown an unsaturated heterocyclic nucleus, said unsaturated heterocyclic nucleus being an imidazole, pyrazole, pyrimidine, pyrazine or pyridazine ring; X.sub.1 is hydrogen, lower alkyl, hydroxyl, trifluoromethyl, benzyl, halogen, amino or ##STR19## in which E' is NH or N-cyano; X.sub.2 is hydrogen or when X.sub.1 is lower alkyl, lower alkyl or halogen; k is 0 to 2 and m is 2 or 3, provided that the sum of k and m is 3 or 4; Y is oxygen, sulphur or NH; E is NR.sub.2 ; R.sub.1 is hydrogen, lower alkyl or di-lower alkylamino-lower alkyl; and R.sub.2 is hydrogen, nitro or cyano, or a pharmaceutically acceptable addition salt thereof with the proviso that X.sub.1 is ##STR20## only when E is NH or N-cyano.
- 7. A method of claim 6 in which the heterocyclic compound is N-cyano-N'-methyl-N"-[2-((4-methyl-5-imidazolyl)-methylthio)ethyl]guanidine or a pharmaceutically acceptable addition salt thereof.
- 8. A method of claim 7 in which the heterocyclic compound is N-cyano-N'-methyl-N"-[2-((4-methyl-5-imidazolyl)-methylthio)ethyl]guanidine in the form of its free base.
- 9. A pharmaceutical composition to inhibit H-2 histamine receptors comprising a pharmaceutical carrier and in an effective amount to inhibit said receptors a heterocyclic compound of the formula: ##STR21## wherein A is such that there is formed together with the carbon atom shown an unsaturated heterocyclic nucleus, said unsaturated heterocyclic nucleus being an imidazole, pyrazole, pyrimidine, pyrazine or pyridazine ring; X.sub.1 is hydrogen, lower alkyl, hydroxyl, trifluoromethyl, benzyl, halogen, amino or ##STR22## in which E' is NH or N-cyano; X.sub.2 is hydrogen or when X.sub.1 is lower alkyl, lower alkyl or halogen; k is 0 to 2 and m is 2 or 3, provided that the sum of k and m is 3 or 4; Y is oxygen, sulphur or NH; E is NR.sub.2 ; R.sub.1 is hydrogen, lower alkyl or di-lower alkylamino-lower alkyl; and R.sub.2 is hydrogen, nitro or cyano, or a pharmaceutically acceptable addition salt thereof with the proviso that X.sub.1 is ##STR23## only when E is NH or N-cyano.
- 10. A pharmaceutical composition of claim 9 in which the heterocyclic compound is N-cyano-N'-methyl-N"-[2-((4-methyl-5-imidazolyl)methylthio)ethyl]guanidine or a pharmaceutically acceptable addition salt thereof.
- 11. A pharmaceutical composition of claim 10 in which the heterocyclic compound is N-cyano-N'-methyl-N"-[2-((4-methyl-5-imidazolyl)methylthio)ethyl]guanidine in the form of its free base.
- 12. A pharmaceutical composition of claim 11 in which the pharmaceutical composition is in the form of a tablet or capsule.
- 13. A pharmaceutical composition of claim 11 in which the heterocyclic compound is present in an amount of from about 50 mg. to about 250 mg.
Priority Claims (1)
Number |
Date |
Country |
Kind |
136/72 |
Feb 1972 |
EI |
|
Parent Case Info
This is a division of application Ser. No. 450,957 filed Mar. 14, 1974, now U.S. Pat. No. 3,950,333, which is a continuation-in-part of Ser. No. 290,584 filed Sept. 20, 1972, now abandoned, which is a continuation-in-part of Ser. No. 230,451 filed Feb. 29, 1972, now abandoned.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
3868457 |
Black et al. |
Feb 1975 |
|
3897444 |
Durant et al. |
Jul 1975 |
|
Divisions (1)
|
Number |
Date |
Country |
Parent |
450957 |
Mar 1974 |
|
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
290584 |
Sep 1972 |
|
Parent |
230451 |
Feb 1972 |
|